Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference?

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

(2018) Peter C Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6: designing specific therapeutics for a complex cytokine

(2018) Christoph Garbers et al.   NATURE REVIEWS DRUG DISCOVERY

Physiological effects of modulating the interleukin-6 axis

(2018) Georg Schett   RHEUMATOLOGY

Interleukin (IL)-6 Inhibits IL-27- and IL-30-Mediated Inflammatory Responses in Human Monocytes

(2018) Carlene Petes et al.   Frontiers in Immunology

The effects of CD14 and IL-27 on induction of endotoxin tolerance in human monocytes and macrophages

(2018) Carlene Petes et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study

(2017) Daniel Aletaha et al.   LANCET

The role of IL-6 in host defence against infections: immunobiology and clinical implications

(2017) Stefan Rose-John et al.   Nature Reviews Rheumatology

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis

(2017) Maria Gabriella Raimondo et al.   Drug Design Development and Therapy

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Sirukumab: A Potential Treatment for Mood Disorders?

(2016) Aileen J. Zhou et al.   ADVANCES IN THERAPY

Improved survival in rheumatoid arthritis: a general population-based cohort study

(2016) Yuqing Zhang et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer

(2016) Chunyan Zhang et al.   IMMUNITY

Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA

(2016) Hisham Abdallah et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells

(2016) Sylvia Heink et al.   NATURE IMMUNOLOGY

Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses’ Health Study

(2016) Jeffrey A. Sparks et al.   ARTHRITIS CARE & RESEARCH

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date

(2016) Pietro Enea Lazzerini et al.   Drug Design Development and Therapy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis

(2016) Brad H. Rovin et al.   Arthritis & Rheumatology

FRI0069 Neutralization of IL6 by Sirukumab (SIR) Inhibits Inflammation and Cellular Stress in a Human Vascular Surrogate System of Atherosclerosis

(2015) R. Feaver et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0182 Improvement in Measures of Depressed Mood and Anhedonia, and Fatigue, In a Randomized, Placebo-Controlled, Phase 2 Study of Sirukumab, A Human Anti-Interleukin-6 Antibody, In Patients with Rheumatoid Arthritis

(2015) B. Hsu et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

(2015) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future

(2015) Go Woon Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Dose selection of siltuximab for multicentric Castleman’s disease

(2015) Christina L. Mayer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Blocking IL-6 trans-Signaling Prevents High-Fat Diet-Induced Adipose Tissue Macrophage Recruitment but Does Not Improve Insulin Resistance

(2015) Michael J. Kraakman et al.   Cell Metabolism

Interleukin-6: Biology, signaling and strategies of blockade

(2015) Fred Schaper et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial

(2015) Tsutomu Takeuchi et al.   Modern Rheumatology

IL-6 as a keystone cytokine in health and disease

(2015) Christopher A Hunter et al.   NATURE IMMUNOLOGY

The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

(2015) Maarten Van Roy et al.   ARTHRITIS RESEARCH & THERAPY

The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-Ra

(2015) Michael E. Weinblatt et al.   Arthritis & Rheumatology

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study

(2015) Mark C. Genovese et al.   Arthritis & Rheumatology

OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA

(2014) J.-B. Holz et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

(2014) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy

(2014) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells

(2014) E. M. Briso et al.   JOURNAL OF IMMUNOLOGY

Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis

(2014) M. A. Nowell et al.   JOURNAL OF IMMUNOLOGY

Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial

(2014) Frits van Rhee et al.   LANCET ONCOLOGY

IL-6 biology: implications for clinical targeting in rheumatic disease

(2014) Leonard H. Calabrese et al.   Nature Reviews Rheumatology

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

(2014) Alan Kivitz et al.   ARTHRITIS CARE & RESEARCH

Nanobodies as modulators of inflammation: potential applications for acute brain injury

(2014) Björn Rissiek et al.   Frontiers in Cellular Neuroscience

Revisiting the 1986 Molecular Cloning of Interleukin 6

(2014) Toshio Hirano   Frontiers in Immunology

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

(2013) Tom W J Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

(2013) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Nanobodies: Natural Single-Domain Antibodies

(2013) Serge Muyldermans   Annual Review of Biochemistry

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy

(2013) Georg Schett et al.   NATURE MEDICINE

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

(2013) Xin Yao et al.   PHARMACOLOGY & THERAPEUTICS

The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis

(2013) F. Matcham et al.   RHEUMATOLOGY

Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities

(2013) Jürgen Scheller et al.   SEMINARS IN IMMUNOLOGY

Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases

(2013) Ricardo C. Ferreira et al.   PLoS Genetics

Interleukin-6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis

(2013) A. Thiolat et al.   Arthritis & Rheumatology

Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study

(2012) Alexis Ogdie et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

(2012) P Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis

(2012) Jan Sodenkamp et al.   IMMUNOBIOLOGY

An Interleukin-6 Receptor-dependent Molecular Switch Mediates Signal Transduction of the IL-27 Cytokine Subunit p28 (IL-30) via a gp130 Protein Receptor Homodimer

(2012) Christoph Garbers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling

(2012) J. Hoge et al.   JOURNAL OF IMMUNOLOGY

The interleukin 6 pathway and atherosclerosis

(2012) Jürgen Scheller et al.   LANCET

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

(2011) Simon A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

Whole-Molecule Antibody Engineering: Generation of a High-Affinity Anti-IL-6 Antibody with Extended Pharmacokinetics

(2011) Donna K. Finch et al.   JOURNAL OF MOLECULAR BIOLOGY

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease

(2010) Frits van Rhee et al.   JOURNAL OF CLINICAL ONCOLOGY

Suppression of TNF-  and IL-1 Signaling Identifies a Mechanism of Homeostatic Regulation of Macrophages by IL-27

(2010) G. D. Kalliolias et al.   JOURNAL OF IMMUNOLOGY

Differences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor

(2010) M. M. McFarland-Mancini et al.   JOURNAL OF IMMUNOLOGY

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

A Meta-Analysis of Cytokines in Major Depression

(2009) Yekta Dowlati et al.   BIOLOGICAL PSYCHIATRY

Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble-IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model

(2009) S. Matsumoto et al.   JOURNAL OF IMMUNOLOGY